DisclosureWe earn commission on partner links; ranking is set by clinician-vetted methodology — not advertisers.
Coverage details, prior authorization criteria, copay ranges, and appeal strategy for 2026. Verified May 1, 2026.
BCBS is a federation — coverage rules vary by state plan (BCBS of Texas ≠ Anthem BCBS California). Most commercial plans cover GLP-1s with prior auth. State plan variance is the biggest hurdle.
Blue Cross Blue Shield requires the following before approving Zepbound:
Top denial patterns we see in 2026 based on appeal-claim data:
OSA-with-obesity pathway (post-Dec 2024 FDA approval) skips weight-loss step therapy. Submit AHI ≥15 sleep study.
State plan Member Services → Pharmacy Appeal → typically 30-day decision window.
Zepbound (tirzepatide 5-15mg) carries the following FDA-approved indications. Off-label use is the #1 PA denial reason — ensure your prescribing diagnosis matches one of these.
Coverage details verified May 1, 2026 against Blue Cross Blue Shield formulary documentation. Formulary changes happen quarterly — always verify against your specific plan before prescribing.